% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Schliesser:130493,
      author       = {M. Schliesser$^*$ and R. Claus$^*$ and T. Hielscher$^*$ and
                      C. Grimm$^*$ and D. Weichenhan$^*$ and J. Blaes$^*$ and B.
                      P. O. Wiestler$^*$ and P. Hau$^*$ and J. Schramm and F.
                      Sahm$^*$ and E. K. Weiß$^*$ and M. Weiler and C. Baer and
                      F. Schmidt-Graf and G. Schackert and M. Westphal and A.
                      Hertenstein$^*$ and P. Roth and N. Galldiks and C. Hartmann
                      and T. Pietsch and J. Felsberg and G. Reifenberger and M. C.
                      Sabel and F. Winkler$^*$ and A. von Deimling$^*$ and C.
                      Meisner and P. Vajkoczy and M. Platten$^*$ and M. Weller and
                      C. Plass$^*$ and W. Wick$^*$},
      title        = {{P}rognostic relevance of mi{RNA}-155 methylation in
                      anaplastic glioma.},
      journal      = {OncoTarget},
      volume       = {7},
      number       = {50},
      issn         = {1949-2553},
      address      = {[S.l.]},
      publisher    = {Impact Journals LLC},
      reportid     = {DKFZ-2017-05572},
      pages        = {82028-82045},
      year         = {2016},
      abstract     = {The outcome of patients with anaplastic gliomas varies
                      considerably depending on single molecular markers, such as
                      mutations of the isocitrate dehydrogenase (IDH) genes, as
                      well as molecular classifications based on epigenetic or
                      genetic profiles. Remarkably, $98\%$ of the RNA within a
                      cell is not translated into proteins. Of those, especially
                      microRNAs (miRNAs) have been shown not only to have a major
                      influence on physiologic processes but also to be
                      deregulated and prognostic in malignancies.To find novel
                      survival markers and treatment options we performed unbiased
                      DNA methylation screens that revealed 12 putative miRNA
                      promoter regions with differential DNA methylation in
                      anaplastic gliomas. Methylation of these candidate regions
                      was validated in different independent patient cohorts
                      revealing a set of miRNA promoter regions with prognostic
                      relevance across data sets. Of those, miR-155 promoter
                      methylation and miR-155 expression were negatively
                      correlated and especially the methylation showed superior
                      correlation with patient survival compared to established
                      biomarkers.Functional examinations in malignant glioma cells
                      further cemented the relevance of miR-155 for tumor cell
                      viability with transient and stable modifications indicating
                      an onco-miRNA activity. MiR-155 also conferred resistance
                      towards alkylating temozolomide and radiotherapy as
                      consequence of nuclear factor (NF)κB
                      activation.Preconditioning glioma cells with an NFκB
                      inhibitor reduced therapy resistance of miR-155
                      overexpressing cells. These cells resembled tumors with a
                      low methylation of the miR-155 promoter and thus mir-155 or
                      NFκB inhibition may provide treatment options with a
                      special focus on patients with IDH wild type tumors.},
      cin          = {G160 / G370 / G380 / C010 / C060 / L101 / L401 / L301},
      ddc          = {610},
      cid          = {I:(DE-He78)G160-20160331 / I:(DE-He78)G370-20160331 /
                      I:(DE-He78)G380-20160331 / I:(DE-He78)C010-20160331 /
                      I:(DE-He78)C060-20160331 / I:(DE-He78)L101-20160331 /
                      I:(DE-He78)L401-20160331 / I:(DE-He78)L301-20160331},
      pnm          = {317 - Translational cancer research (POF3-317)},
      pid          = {G:(DE-HGF)POF3-317},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:27880937},
      pmc          = {pmc:PMC5347671},
      doi          = {10.18632/oncotarget.13452},
      url          = {https://inrepo02.dkfz.de/record/130493},
}